Scarica l'app Stockscreener
0.699
13.81%
0.0848
Dopo l'orario di chiusura:
.70
0.001
+0.14%
Virpax Pharmaceuticals Inc Borsa (VRPX) Ultime notizie
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering - The Manila Times
Virpax Pharmaceuticals Raises $5M to Advance Pain Management Drug Development | VRPX Stock News - StockTitan
Virpax Pharmaceuticals Prices of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants - citybiz
Virpax Pharmaceuticals prices $5 million stock offering - Investing.com
Virpax Pharmaceuticals Raises $5M in Public Offering to Advance Pain Management Drug | VRPX Stock News - StockTitan
Closing Bell Recap: Virpax Pharmaceuticals Inc (VRPX) Ends at 0.48, Reflecting a 1.06 Upturn - The Dwinnex
Virpax Pharmaceuticals Inc: Navigating a Turbulent Year, Up -95.58% from 52-Week Low - The InvestChronicle
VRPX stock touches 52-week low at $0.46 amid market challenges - Investing.com India
Maxim Group Downgrades Virpax Pharmaceuticals (VRPX) - MSN
Virpax Pharmaceuticals, Inc. Announces Board and Committee Changes - Marketscreener.com
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com India
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals appoints new Vice President - Investing.com India
Virpax Pharmaceuticals extends financing negotiation rights - Investing.com
Virpax Pharmaceuticals extends financing negotiation rights By Investing.com - Investing.com Australia
Virpax Pharmaceuticals appoints new Vice President By Investing.com - Investing.com UK
Virpax Pharmaceuticals announces auditor change and board resignation By Investing.com - Investing.com Canada
Virpax Pharmaceuticals announces auditor change and board resignation - Investing.com
Virpax Pharmaceuticals Overhauls Leadership and Auditor Amid Concerns - TipRanks
Checking in on Vir Biotechnology Inc (VIR) after recent insiders movement - Knox Daily
Visionstate (CVE:VIS) Trading 25% Higher - Defense World
Investing in Viridian Therapeutics Inc (VRDN) Is Getting More Attractive - Knox Daily
Virpax Pharmaceuticals sees board member departure By Investing.com - Investing.com Canada
Virpax Pharmaceuticals sees board member departure - Investing.com
Virpax Pharmaceuticals Announces Key Management Changes - TipRanks
Faruqi & Faruqi Reminds Vicor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 23, 2024VICR - PR Newswire
It makes sense and dollars to buy Viridian Therapeutics Inc (VRDN) stock - SETE News
Virax Biolabs Group Ltd Inc. (VRAX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
A closer look at VRAX’s price-to-free cash flow ratio - US Post News
VRDN (Viridian Therapeutics Inc) has impressive results - US Post News
Virpax Pharmaceuticals Inc (VRPX) is looking forward to a strong quarter - SETE News
Virpax Pharmaceuticals Inc (VRPX)’s Market Momentum: Closing Strong at 0.82, Up 0.99 - The Dwinnex
Can you still get a good price for Virpax Pharmaceuticals Inc (VRPX) Shares at this point? - US Post News
Virpax Pharmaceuticals receives $2.5M loan financing - Pennsylvania Business Report
Virpax Pharmaceuticals Inc (VRPX)’s stock rises to 1.20 per share - US Post News
Virpax Pharmaceuticals Reports Q2 2024 Financial Results and Strategic Progress - MyChesCo
Virpax Pharmaceuticals Inc: Navigating Market Fluctuations with a 5.77M Market Cap - The InvestChronicle
Daily Progress: Virpax Pharmaceuticals Inc (VRPX) Gain 8.12, Closing at 0.92 - The Dwinnex
VRPX (Virpax Pharmaceuticals) Momentum Rank : 2 (As of Aug. 20, 2024) - GuruFocus.com
VRPX (Virpax Pharmaceuticals) EV-to-Revenue : (As of Aug. 19, 2024) - GuruFocus.com
VRPX (Virpax Pharmaceuticals) 3-Year FCF Growth Rate : -39.90% (As of Jun. 2024) - GuruFocus.com
VRPX (Virpax Pharmaceuticals) 3-Year EPS without NRI Growth Rate : -13.40% (As of Jun. 2024) - GuruFocus.com
Virpax Pharmaceuticals to Present at Sidoti August Virtual Investor Conference - MyChesCo
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Decline in Short Interest - Defense World
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments - Business Wire
VRPX Stock Earnings: Virpax Pharmaceuticals Reported Results for Q2 2024 - InvestorPlace
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 - Business Wire
Marinus Pharmaceuticals to Announce Q2 Financial Results - MyChesCo
Virpax Pharmaceuticals Regains Nasdaq Compliance - MSN
Virpax Pharmaceuticals gains compliance extension from Nasdaq - Investing.com India
Virpax Pharmaceuticals gains compliance extension from Nasdaq By Investing.com - Investing.com Australia
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):